by 
The biosimilar pipeline analysis market covers monitoring services for biosimilar applications, providing reports with development stage of drug candidates, clinical trials details, regulatory and patent status across different geographical regions. Biosimilars aim to provide affordable biologic treatment options as they are developed to be highly similar to an already approved biologic product.
The Global Biosimilar Pipeline Analysis Market is estimated to be valued at US$ 29.4 Bn in 2024 and is expected to exhibit a CAGR of 17% over the forecast period 2023 to 2030.
Key Takeaways
Key players: Key players operating in the biosimilar pipeline analysis are Pfizer Inc. (AC. Hospira), Amgen, Biocon, Dr. Reddy’s Laboratories, Celltrion, Mylan, Samsung Bioepis and Teva Pharmaceutical. With the increasing patents expiries of blockbuster biologics in the coming years, there is an immense opportunity for biosimilar manufacturers to enter the market. According to DelveInsight estimates, more than 100 biosimilar drugs will get approval by 2026, which will lead to immense cost-savings.
Pfizer Inc. (AC. Hospira) is a leading player in biosimilar pipeline analysis market with robust pipeline of products.
Growing demand: There is growing demand for affordable treatment options driving the demand for biosimilars. With patents of biologics like Humira, Avastin and Rituxan expiring, biosimilar manufacturers are eyeing the market potential.
Global expansion: Leading players are expanding their manufacturing capacities across regions like North America, Europe and Asia Pacific to cater to growing demand. Partnerships with local players is another strategy adopted.
Market key trends
One of the key trends witnessed in the biosimilar pipeline analysis market is the increasing number of patent expiries of blockbuster biologics. Drugs like Humira, Avastin, Rituxan and others will lose their data and market exclusivity in coming years. This will open lucrative opportunities for biosimilar players to commercialize follow on biological products. While biosimilars were initially focused on Europe and emerging markets, their adoption is gradually increasing in the US as well due to cost benefits.
Porter’s Analysis
Threat of new entrants: High capital investment requirements pose an entry barrier.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over smaller biosimilar developers.
Bargaining power of suppliers: Suppliers of raw materials and active pharmaceutical ingredients have some bargaining power.
Threat of new substitutes: Potential for new biologics to replace older biologics over time poses a threat.
Competitive rivalry: Increasing competition as patents expire on blockbuster biologics intensifies price competition.
Geographical Regions
North America currently dominates the global biosimilar pipeline market in terms of value, accounting for over 35% market share in 2023. A favourable regulatory environment and presence of major players drive the large size of the North American market.
Asia Pacific is projected to be the fastest growing regional market, expanding at a CAGR of 21% through 2030. Improving healthcare infrastructure and increasing focus of international players on countries like China, India, South Korea and Japan are supporting market growth. Rising middle class populations with greater access to healthcare will propel biosimilar adoption in Asia Pacific.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
